Abstract:
In this study, structural optimization of borneol was carried out to improve their solubility and promote their further application in stroke therapy.
BP-3, a prodrug of borneol, was designed and synthesized based on the principle of phosphate modification. The solubility of
BP-3 was determined by evaporative light scattering detector (ELSD), and the degree and speed of drug release were tested in mouse plasma, and the neuroprotective effect of
BP-3 was evaluated in mouse model of transient middle cerebral artery occlusion (tMCAO). According to the results,
BP-3 was completely soluble in saline at 20 mg/mL; in mouse plasma, approximately 40% of the borneol were released within 2 h; in the tMCAO mouse model, TTC staining showed that
BP-3 was effective in reducing the infarct area; Nissl staining showed that
BP-3 ameliorated the neuronal injury; the grip and grasping strength tests elucidated that
BP-3 reduced the damage of sports ability caused by injury; and the rotating rod test proved that
BP-3 could promote the recovery of motor ability in mice.
BP-3 has good water solubility, suitable drug release rate and excellent neuroprotective effects, and has broad prospects for drug development.